A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward

Wang, Bo; Van Oekelen, Oliver; Mouhieddine, Tarek H.; Valle, Diane Marie Del; Richter, Joshua; Cho, Hearn Jay; Richard, Shambavi; Chari, Ajai; Gnjatic, Sacha; Merad, Miriam; Jagannath, Sundar; Parekh, Samir; Madduri, Deepu

BACKGROUND: The COVID-19 pandemic, caused by SARS-CoV-2 virus, has resulted in over 100,000 deaths in the United States. Our institution has treated over 2,000 COVID-19 patients during the pandemic in New York City. The pandemic directly impacts cancer patients and the organization of cancer care. Mount Sinai Hospital has a large and diverse multiple myeloma population. Here, we report the characteristics of COVID-19 infection and serological response in multiple myeloma (MM) patients in a large tertiary care institution in New York. METHODS: We performed a retrospective study of a cohort of 58 patients with a plasma cell disorder (54 MM, 4 smoldering MM) who developed COVID-19 between March 1, 2020 and April 30, 2020. We report epidemiological, clinical and laboratory characteristics including persistence of viral detection by polymerase chain reaction (PCR) and anti-SARS-CoV-2 antibody testing, treatments initiated, and outcomes. RESULTS: Of the 58 patients diagnosed with COVID-19, 36 were hospitalized and 22 were managed at home. The median age was 67 years; 52% of patients were male and 63% were non-white. Hypertension (64%), hyperlipidemia (62%), obesity (37%), diabetes mellitus (28%), chronic kidney disease (CKD, 24%) and lung disease (21%) were the most common comorbidities. In the total cohort, 14 patients (24%) died. Older age (>70 years), male sex and cardiovascular risk were significantly (p<0.05) associated with hospitalization. Among hospitalized patients, laboratory findings demonstrated elevation of traditional inflammatory markers (CRP, ferritin, D-dimer) and a significant (p<0.05) association between elevated inflammatory markers, severe hypogammaglobulinemia, non-white race, and mortality. Ninety-six percent (22/23) of patients developed antibodies to SARS-CoV-2 at a median of 32 days after initial diagnosis. Median time to PCR negativity was 43 (range 19-68) days from initial positive PCR. CONCLUSIONS: Drug exposure and MM disease status at the time of contracting COVID-19 had no bearing on patient outcome. Mounting a severe inflammatory response to SARS-CoV-2, and severe hypogammaglobulinemia were associated with higher mortality. These findings pave a path to identification of vulnerable patients who need early intervention to improve outcome of myeloma patients in future outbreaks of COVID-19. The majority of myeloma patients mounted a specific antibody response to SARS-CoV-2.